![Patient in AIDS hospital](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/5553x3707+0+0/resize/1100/quality/85/format/webp/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fad%2Ff9%2Fc51ae7014aa3aea046c3f6ee8733%2Fgettyimages-1238336784.jpg)
For over a decade, taking a pill like Truvada every day has been the standard of care for HIV prevention efforts.
In clinical trials, this type of preventive drug, called pre-exposure prophylaxis (PrEP), can be 99% effective in stopping new HIV infections from sex. In the real world, however, that is not always the case.
People don’t always take their pills. In a study in South Africa, women said they felt there was a stigma to the pill —- a sexual partner might assume they’re taking it because they already have HIV or because they have other partners.
Now a new trial —- called PURPOSE 1 —- points the way to a new preventive strategy —- a twice yearly injection of a drug called lenacapavir. The trial was sponsored by Gilead Sciences, the California-based maker of the drug.